Q: How does Takhzyro work?

Mechanism of Action Takhzyro (lanadelumab-flyo) is a monoclonal antibody designed to prevent attacks of hereditary angioedema (HAE). It works by targeting the biological pathway that leads to the sudden, severe swelling characteristic of the condition. The Role of Bradykinin In people with HAE, the body produces excessive amounts of a protein called bradykinin . Bradykinin is a substance that causes blood vessels to dilate and leak fluid into nearby tissues. When this leakage happens rapidly, it results in the painful and potentially dangerous swelling episodes associated with HAE. How Takhzyro Intervenes Takhzyro helps control the production of bradykinin by targeting an enzyme called plasma kallikrein . The process works as follows: Binding to Plasma Kallikrein: Takhzyro is engineered to bind specifically to plasma kallikrein, an enzyme that is overactive in people with HAE. Inhibiting Enzyme Activity: Plasma kallikrein is responsible for releasing bradykinin. By binding to and inhibiting this enzyme, Takhzyro limits its ability to produce bradykinin. Reducing Swelling Attacks: By keeping bradykinin levels lower and more stable, Takhzyro helps prevent blood vessels from leaking, thereby reducing the frequency of HAE attacks. Because Takhzyro works to prevent the chemical chain reaction that leads to swelling, it is used as a long-term preventive treatment rather than a rescue medication for active attacks.

Q: What are the active ingredients in Takhzyro?

The active ingredient in Takhzyro is lanadelumab .

Q: What are the side effects of Takhzyro?

Common side effects of Takhzyro may include: injection site reactions headache fatigue Always consult with a healthcare professional about potential side effects.

Q: What drug class is Takhzyro?

Takhzyro belongs to the monoclonal antibody drug class.

Q: What is the dosage of Takhzyro and how do I take it?

Administration Takhzyro is given as an injection under the skin (subcutaneously). Common injection sites include the abdomen, the front of the thighs, or the back of the upper arms. It is important to rotate the injection site with each dose. A healthcare professional will provide training on how to properly prepare and inject the medication. Once trained, patients or their caregivers may administer the injection at home. Dosing Schedule This medication is intended for long-term prevention and is typically injected every two weeks. Depending on how well the condition is controlled, a healthcare provider may eventually adjust the schedule to one injection every four weeks. Preparation Remove the medication from the refrigerator and allow it to reach room temperature before use. Do not shake the vial or prefilled syringe. Check the liquid for particles or discoloration before injecting. The solution should be clear to slightly yellow. Each vial or syringe is for single use only. Missed Dose If a dose is missed, it should be taken as soon as possible. However, two doses should not be administered at the same time. Patients should contact their healthcare provider for guidance on the appropriate interval between doses if a schedule is interrupted.

Q: Is Takhzyro safe during pregnancy and breastfeeding?

Pregnancy There is limited data on the use of Takhzyro in pregnant women. While animal studies did not show evidence of harm to the fetus, it is not yet known if the medication is safe for use during human pregnancy. Takhzyro is a monoclonal antibody, and these types of drugs are known to cross the placenta, especially during the later stages of pregnancy. If you are pregnant or planning to become pregnant, discuss the potential benefits and risks with your healthcare provider to determine if this treatment is appropriate for you. Breastfeeding It is not known if Takhzyro passes into breast milk or if it has any effect on a breastfed infant or milk production. The decision to breastfeed while using this medication should involve a discussion with a healthcare provider to weigh the benefits of breastfeeding against the mother's medical need for the drug.

Q: What is the FDA approval status of Takhzyro?

FDA Approval History The U.S. Food and Drug Administration (FDA) first approved Takhzyro in August 2018. It was the first monoclonal antibody approved to prevent attacks of hereditary angioedema (HAE). During its development, the medication received several regulatory designations, including orphan drug, breakthrough therapy, and priority review status. Approved Indications Takhzyro is indicated for routine prophylaxis to prevent attacks of hereditary angioedema (HAE). While initially approved for patients 12 years of age and older, the FDA later expanded the approved use to include pediatric patients as young as 2 years of age. It is intended for preventive use only and is not indicated for the treatment of acute HAE attacks. Regulatory Status and Safety Takhzyro is a prescription-only biological product. According to current FDA-approved labeling, there are no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements associated with this medication. Regulatory approval was based on clinical trials demonstrating that the drug significantly reduced the rate of monthly HAE attacks compared to a placebo.

Question 1

What is Takhzyro?

Accepted Answer

Takhzyro is a laboratory-made protein known as a monoclonal antibody that targets a specific enzyme in the blood called plasma kallikrein. By binding to and inhibiting this enzyme, the medication helps regulate the production of bradykinin, which is a substance that causes blood vessels to dilate and leak fluid into body tissues.

Controlling the activity of plasma kallikrein helps to limit the underlying biological processes that lead to episodes of severe swelling and inflammation. This preventive approach focuses on managing the body's internal chemical reactions to maintain stability and reduce the frequency of symptomatic flares.

Question 2

What is Takhzyro used for?

Accepted Answer

Takhzyro is used to treat routine prevention of hereditary angioedema attacks.

Question 3

How does Takhzyro work?

Accepted Answer

Mechanism of Action

Takhzyro (lanadelumab-flyo) is a monoclonal antibody designed to prevent attacks of hereditary angioedema (HAE). It works by targeting the biological pathway that leads to the sudden, severe swelling characteristic of the condition.

The Role of Bradykinin

In people with HAE, the body produces excessive amounts of a protein called bradykinin. Bradykinin is a substance that causes blood vessels to dilate and leak fluid into nearby tissues. When this leakage happens rapidly, it results in the painful and potentially dangerous swelling episodes associated with HAE.

How Takhzyro Intervenes

Takhzyro helps control the production of bradykinin by targeting an enzyme called plasma kallikrein. The process works as follows:

Binding to Plasma Kallikrein: Takhzyro is engineered to bind specifically to plasma kallikrein, an enzyme that is overactive in people with HAE.
Inhibiting Enzyme Activity: Plasma kallikrein is responsible for releasing bradykinin. By binding to and inhibiting this enzyme, Takhzyro limits its ability to produce bradykinin.
Reducing Swelling Attacks: By keeping bradykinin levels lower and more stable, Takhzyro helps prevent blood vessels from leaking, thereby reducing the frequency of HAE attacks.

Because Takhzyro works to prevent the chemical chain reaction that leads to swelling, it is used as a long-term preventive treatment rather than a rescue medication for active attacks.

Question 4

What are the active ingredients in Takhzyro?

Accepted Answer

The active ingredient in Takhzyro is lanadelumab.

Question 5

What are the side effects of Takhzyro?

Accepted Answer

Common side effects of Takhzyro may include:

injection site reactions
headache
fatigue

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Takhzyro?

Accepted Answer

Takhzyro belongs to the monoclonal antibody drug class.

Question 7

What is the dosage of Takhzyro and how do I take it?

Accepted Answer

Administration

Takhzyro is given as an injection under the skin (subcutaneously). Common injection sites include the abdomen, the front of the thighs, or the back of the upper arms. It is important to rotate the injection site with each dose.

A healthcare professional will provide training on how to properly prepare and inject the medication. Once trained, patients or their caregivers may administer the injection at home.

Dosing Schedule

This medication is intended for long-term prevention and is typically injected every two weeks. Depending on how well the condition is controlled, a healthcare provider may eventually adjust the schedule to one injection every four weeks.

Preparation

Remove the medication from the refrigerator and allow it to reach room temperature before use.
Do not shake the vial or prefilled syringe.
Check the liquid for particles or discoloration before injecting. The solution should be clear to slightly yellow.
Each vial or syringe is for single use only.

Missed Dose

If a dose is missed, it should be taken as soon as possible. However, two doses should not be administered at the same time. Patients should contact their healthcare provider for guidance on the appropriate interval between doses if a schedule is interrupted.

Question 8

Is Takhzyro safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited data on the use of Takhzyro in pregnant women. While animal studies did not show evidence of harm to the fetus, it is not yet known if the medication is safe for use during human pregnancy. Takhzyro is a monoclonal antibody, and these types of drugs are known to cross the placenta, especially during the later stages of pregnancy.

If you are pregnant or planning to become pregnant, discuss the potential benefits and risks with your healthcare provider to determine if this treatment is appropriate for you.

Breastfeeding

It is not known if Takhzyro passes into breast milk or if it has any effect on a breastfed infant or milk production. The decision to breastfeed while using this medication should involve a discussion with a healthcare provider to weigh the benefits of breastfeeding against the mother's medical need for the drug.

Question 9

What forms and strengths does Takhzyro come in?

Accepted Answer

Takhzyro is supplied as a sterile solution for injection under the skin. It comes in two primary delivery formats:

Single-dose prefilled syringe: A ready-to-use syringe containing the medication.
Single-dose vial: A glass vial containing the medication that requires a separate syringe for administration.

The solution is clear to slightly yellow and does not contain preservatives. Each container is intended for a single use only.

Question 10

What is the FDA approval status of Takhzyro?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) first approved Takhzyro in August 2018. It was the first monoclonal antibody approved to prevent attacks of hereditary angioedema (HAE). During its development, the medication received several regulatory designations, including orphan drug, breakthrough therapy, and priority review status.

Approved Indications

Takhzyro is indicated for routine prophylaxis to prevent attacks of hereditary angioedema (HAE). While initially approved for patients 12 years of age and older, the FDA later expanded the approved use to include pediatric patients as young as 2 years of age. It is intended for preventive use only and is not indicated for the treatment of acute HAE attacks.

Regulatory Status and Safety

Takhzyro is a prescription-only biological product. According to current FDA-approved labeling, there are no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements associated with this medication. Regulatory approval was based on clinical trials demonstrating that the drug significantly reduced the rate of monthly HAE attacks compared to a placebo.

Question 11

What should I know about Takhzyro and cost?

Accepted Answer

Insurance and Prior Authorization

Most insurance plans cover Takhzyro, but they often require prior authorization. This is a process where your healthcare provider must get approval from your insurance company before the plan will pay for the medication. Your actual cost will depend on your specific insurance plan, including your deductible and copay amounts.

Specialty Pharmacy

Takhzyro is a specialty drug and is usually only available through specialty pharmacies. These pharmacies specialize in medications that require special handling, such as refrigeration, and may provide additional support for managing your treatment.

Financial Assistance Programs

The manufacturer of Takhzyro offers programs to help reduce the cost for eligible patients. These may include:

Copay Assistance: For patients with commercial insurance, this can help lower out-of-pocket costs.
Patient Assistance Programs: These programs may provide the medication at no cost to patients who meet certain income and insurance requirements.

Generic Versions

There is currently no generic or biosimilar version of Takhzyro available. As a biologic medication, it is protected by patents that prevent other manufacturers from creating identical versions for a period of time.

Takhzyro

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Takhzyro

Hospitals.net Disclosure